In the next quarter, the owner of a revolutionary technology supporting breast cancer diagnostics is planning to place the device on the Polish market. The Company has successfully conducted first production trials of the device and completed its work on a mobile app for women. Currently, BRASTER is in the process of obtaining a certificate of conformity (CE) – the first stage of this procedure has been successfully ended.

"The pace of realisation of specific works is impressive, taking into account how complex the tasks performed by our staff are. We are in the home straight to achieve our aim, that is to commercialise our device. The finished product will be placed on the Polish market in the fourth quarter," says President of the Management Board of BRASTER S.A. Marcin Halicki.

The Braster device will be the world’s first device supporting breast cancer prevention, addressing directly women.

In the first week of August, BRASTER successfully completed the second production trial run of the Braster device, as part of which 100 products were manufactured. The run was conducted in Białystok, in Rosti factory, which is a key partner of the Company. During the run, a special assembly line simulating production conditions was used. The devices produced in the trial run have been tested for functionality by engineers from the Product Development Department and fully assembled. The next step is the third and final production trial, during which 100 new devices will be made. After the third trial, the Company will smoothly shift to mass production.

At the same time, BRASTER completed its works on an updated version of the mobile app, which will be necessary to undertake examination, leading the woman through the whole test procedure. The system will be installed on mobile devices – tablets or smartphones. Currently, the Company has started work to place the application in Google and Apple shops.

The current actions taken by the Company are also focused on the process of obtaining a certificate of conformity (CE), which is to be issued by a notified body, TUV Nord Polska, following the necessary certification procedure. After completion of the whole conformity assessment, the Company will be able to notify the medical device to the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) and then place it on the market in Poland and the EU. At the same time, BRASTER is carrying out intensive negotiations with Poland’s leading pharmacy chains on conditions of sale of the device in their stores.

The Company is also completing work on launching a widespread marketing campaign targeting directly women. In its communication, BRASTER will use such channels as social media, Internet, VOD, YouTube, women’s press, billboards and selected TV programmes.

Completion of the above-mentioned projects will be a key value in realisation of the Company’s development strategy. If the Braster device is successfully commercialised on the Polish and international markets, the BRASTER business will start to generate considerable revenues, which will strategically influence the future financial results of the Company.